

Special Issue

Proteins and Peptides as a Treatment for Cardiovascular Disease: From Bacteria to Human

Message from the Guest Editor

Protein and peptide dysregulation is well documented in processes such as metabolic diseases, obesity, atherosclerosis, diabetes mellitus, heart failure or even other pathologies, like cancer. Nevertheless, the role of these molecules as major mediators of cell, and tissue injury/damage needs to be studied in depth. Pathogen proteins or autologous proteins/peptides can act as strong modulators, with beneficial therapeutic values for their potential use as candidate targets in heart, kidney or lung by autocrine-, paracrine-, endocrine-, and pathogen-induced diseases. This Special Issue aims to explore the uses of proteins and peptides in silico, in vitro, and in vivo as novel therapeutic tools in the development of potent cell modulators or immunomodulators to block pathogens or to enhance protection against self-dysregulated mechanisms related to the development of cardiovascular diseases. We invite you to submit original works, research papers, reviews, and short communications.

Guest Editor

Dr. Guerrero-Beltrán Carlos Enrique

Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Medicina Cardiovascular y Metabólica, Monterrey 64710, Mexico

Deadline for manuscript submissions

closed (30 November 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/103993

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).